FDA
-
-
-
-
-
-
-
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
-
-
-
-
-
-
-
Rodman & Renshaw Starts BioXcel Therapeutics (BTAI) at Buy, PT $17
-
-
-
-
-
-
-
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
-
-
-
-
-
-
-
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
-
-
-
-
-
-
-
BioXcel announces positive results from IGALMI at-home trial
-
-
-
-
-
-
-
BioXcel completes database lock for BXCL501 agitation trial
-
-
-
-
-
-
-
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
-
322,184 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

